Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 13vPnC in Chinese Infants and Children
NCT03574389Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2018
- Primary completion
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Prevnar 13 in pneumococcal infection (2 arms), sponsored by Pfizer. Primary endpoints: Serotype-specific Immunoglobulin G Geometric Mean Concentrations, Number of Participants With Local Reactions and 3 more. Started Jun 2018; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03574389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574389.